Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Kenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Wraparound care for patients taking GLP-1 agonists must include assessment of nutritional status to identify the risk of malnutrition, writes Ellen Fallows Food insecurity is increasing, particularly ...

Binge eating disorder is strongly associated with weight gain and obesity, though not all individuals with obesity have BED.

GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in ...

A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast cancer caused by obesity.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

The researchers estimate 6.5 billion years of life will likely be lost globally due to premature deaths caused by obesity’s negative health effects. The weight loss drugs could lead to a disruptive ...

A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% total body weight lost.